ST Pharm Appoints New CEO Sung Moo-je

ST Pharm has appointed Sung Moo-je as the new CEO. The company aims to leverage Sung's expertise and extensive global network to expand its connections with international pharmaceutical firms, build an R&D pipeline, reorganize existing operations, and develop new business strategies. Sung, a chemistry graduate from Korea University with advanced studies in organic chemistry and postdoctoral work at Harvard, previously worked at Novartis for nearly 20 years. There, he co-developed the FDA-approved breast cancer drug Kisqali. Recently, he led ST Pharm's collaboration with Intheron Laboratories on TNFR inhibitors. ST Pharm, transitioning from a generic drug manufacturer to an oligonucleotide therapeutics CDMO, is also gearing up for a full-scale mRNA CDMO business, boasting its own capping and LNP drug delivery technologies for RNA-based drug development and production.